You're asking about a compound with a rather complex name: **1-[oxo-(2-oxo-1-benzopyran-3-yl)methyl]-4-piperidinecarboxylic acid methyl ester**. This is a chemical compound that is likely a derivative of **coumarin**.
Here's a breakdown of the name and why it's important for research:
**1. Structure and Name Breakdown:**
* **Coumarin (2-oxo-1-benzopyran)** is a naturally occurring compound found in many plants, known for its sweet aroma.
* **oxo-(2-oxo-1-benzopyran-3-yl)methyl** indicates that a coumarin molecule has been modified:
* A carbonyl group (C=O) has been attached at the 3-position of the coumarin ring.
* This carbonyl group is then linked to a methylene (-CH2-) group.
* **1-[oxo-(2-oxo-1-benzopyran-3-yl)methyl]-4-piperidinecarboxylic acid** means this modified coumarin is attached to a piperidine ring (a six-membered heterocyclic ring containing nitrogen). The attachment is at position 1 of the piperidine ring. The 4-position on the piperidine ring also has a carboxylic acid group.
* **methyl ester** means the carboxylic acid group is converted into an ester by reacting it with methanol.
**2. Research Importance:**
**Coumarin derivatives** are well-known for their diverse pharmacological activities, including:
* **Anti-inflammatory:** Some coumarin derivatives have shown anti-inflammatory properties, potentially useful in treating conditions like arthritis.
* **Anticoagulant:** Warfarin, a well-known blood thinner, is a coumarin derivative.
* **Antibacterial and antifungal:** Certain coumarins exhibit antimicrobial properties, making them potential candidates for drug development.
* **Anti-cancer:** Research has suggested that some coumarins might possess anti-cancer activity, potentially affecting tumor growth.
**The specific compound you asked about, 1-[oxo-(2-oxo-1-benzopyran-3-yl)methyl]-4-piperidinecarboxylic acid methyl ester, is likely a synthetic derivative of coumarin. Its exact properties and research importance would depend on the specific study and researchers involved.**
**To understand its specific importance, you'd need to know more about the research context:**
* **What specific properties are being investigated?** (e.g., anti-inflammatory, antimicrobial, etc.)
* **What model systems are being used?** (e.g., cell cultures, animal models)
* **What are the researchers' goals?** (e.g., drug development, understanding biological mechanisms)
**Research papers and databases focusing on coumarin derivatives could provide more specific information about this compound's importance.**
ID Source | ID |
---|---|
PubMed CID | 2235340 |
CHEMBL ID | 1416916 |
CHEBI ID | 108236 |
Synonym |
---|
MLS000538604 , |
methyl 1-[(2-oxo-2h-chromen-3-yl)carbonyl]-4-piperidinecarboxylate |
smr000144641 |
CHEBI:108236 |
AKOS002235540 |
methyl 1-(2-oxochromene-3-carbonyl)piperidine-4-carboxylate |
STK852479 |
methyl 1-[(2-oxo-2h-chromen-3-yl)carbonyl]piperidine-4-carboxylate |
HMS2445C04 |
methyl 1-(2-oxo-2h-chromene-3-carbonyl)piperidine-4-carboxylate |
833433-76-4 |
F3055-0141 |
CHEMBL1416916 |
Q27186931 |
1-[oxo-(2-oxo-1-benzopyran-3-yl)methyl]-4-piperidinecarboxylic acid methyl ester |
sr-01000298336 |
SR-01000298336-1 |
VU0159122-3 |
Class | Description |
---|---|
coumarins | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.3313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 19.4763 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.9811 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 5.6234 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.1623 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |